The Promise of Peptide Therapeutics
PTG-100 PTG-200 PTG-300
October 21, 2020Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera More

Welcome to Protagonist, a clinical-stage biopharmaceutical company poised to deliver life-changing therapies.

Clinical-stage new peptide entities addressing unmet medical needs

Learn More

Executive team with broad industry experience and success in drug development

Learn More

Collaborations with pharma giants and grassroots advocates

Learn More